Developing life-changing therapies for complex neurological disorders with axonal dysfunction


Therapeutic Focus

Toward a Cure for neuromuscular and neurodegenerative disorders

We’re Augustine Therapeutics, a biotech company driven by a clear purpose: to transform the lives of patients suffering from severe peripheral nerve disorders, in particular the rare hereditary disorder Charcot-Marie-Tooth (CMT), but also other axonal degeneration induced by chemotherapy (CIPN). Our driving force is to advance the knowledge of axonal protection, regeneration, and remyelination and its translation into effective therapies for patients with unmet medical needs.

We are developing novel therapeutics that can achieve reinnervation, aiming to slow down and even reverse the disease and provide significant relief for patients affected by axonopathies. Our assets also have potential applications in other complex neurological disorders.

Learn more about our therapeutic focus



Pipeline

We currently have multiple programs in development: our lead project targeting peripherally restricted and selective HDAC6i for CMT and CIPN is advancing into in regulatory preclinical development; our second program focusing on brain penetrant and selective HDAC6i is currently in lead optimization.


About Us

Founded in 2019, Augustine Therapeutics is a biotech company in Leuven, Belgium.

The company is rooted in the groundbreaking research of the VIB laboratory of Ludo Van Den Bosch and in the collaboration between the VIB labs of Joris de Wit and Bart De Strooper.

Supported by an advisory board of leading international experts, our experienced team develops innovative, best-in-class therapeutics to address the great unmet need for the treatment of neuromuscular and neurodegenerative disorders.

More about us

Sylvain Celanire, PhD - Chief Executive Officer
Marie Trad, MD - Chief Medical Officer
Christophe Van Vaeck, PhD - Chief Financial Officer
Frederik Rombouts, PhD - Head of Medicinal Chemistry
Jonathan van Eyll, PhD - Head of Pharmacology
Cédric Szyndralewiez, MSc - Head of Non-Clinical and Early Development

Management

Sylvain has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector

Management

Marie has more than 30 years of experience in clinical and pharmaceutical development experience in the field of Neurology and Neuroradiology

Management

Christophe with more than 20 years of operational and strategic experience in the Life Sciences financial community

Management

Frederik has 20 years of drug discovery research and development experience in the neuroscience and oncology therapeutic areas

Management

Jonathan has more than 18 years of experience in advancing various therapeutic modalities in Neuroscience drug discovery research through translational pharmacoclogy and bioinformatics

Management

Cédric has 25 years of experience in preclincial research and early clinical development in the therapeutic areas of inflammation, neurology, fibrosis and oncology

All our team members


thinline.be | soon production